The genetic engineering industry focuses on modifying organisms at the molecular level to enhance their capabilities or produce valuable substances. Companies in this sector range from biotechnology firms developing gene therapies to those specializing in genome editing technologies like CRISPR. This field is rapidly advancing, with innovations promising breakthroughs in treating genetic disorders, improving crop resilience, and developing more efficient bioprocesses. Current trends point toward increasing collaboration between academia and industry, a surge in investment, and a growing emphasis on personalized medicine as the future direction of genetic engineering.

The companies in this listing represent a mix of sizes, from small teams of fewer than 10 to large corporations over 1,000 employees. Headquartered across the globe, they include locations from North America to Asia. Founded between 1998 and 2023, these companies specialize in areas ranging from gene therapy to CRISPR-based applications. Each company aims to drive innovation in biotechnology, showcasing diverse technologies and methodologies tailored to current health and agricultural challenges.

Read on to discover the top genetic engineering companies.

Top 24 Genetic Engineering Companies

1. Spark Therapeutics, Inc.

• Website: sparktx.com
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing gene therapy treatments for genetic diseases. The company has made significant strides in addressing conditions like hemophilia and inherited retinal diseases, aiming to transform patient care through innovative therapies. Spark operates a fully integrated model that combines research, development, and manufacturing of gene therapies. Their proprietary adeno-associated viral (AAV) gene therapy platform is central to their approach, allowing for targeted treatment of specific genetic disorders. Spark's commitment to patient care is evident in their ongoing research programs and collaborations with healthcare professionals. In 2019, they secured substantial funding of $4.3 billion, which underscores investor confidence in their mission and potential. The establishment of their Gene Therapy Innovation Center in West Philadelphia marks a significant investment in their capabilities, positioning them as a key player in the gene therapy field.

2. Synthego Corporation

• Website: synthego.com
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series E-K, $200.0M, February 2022
• Founded year: 2012
• Headcount: 201-500
• LinkedIn: synthego-corporation

Synthego Corporation, founded in 2012 and based in Menlo Park, California, is a biotechnology company that specializes in genome engineering and CRISPR technology. The company provides a comprehensive range of CRISPR reagents and solutions tailored for academic researchers and biotech firms. Their offerings include high-fidelity nucleases, guide RNA, and regulatory support, which help clients navigate the complexities of CRISPR applications. Synthego leverages automation and machine learning to synthesize high-quality CRISPR reagents at scale, making significant contributions to life science research and development. The company has been involved in numerous peer-reviewed publications and is utilized by thousands of researchers and therapeutic developers. In February 2022, Synthego raised $200 million in Series E funding, further solidifying its position in the biotechnology sector.

3. Arbor Biotechnologies

• Website: arbor.bio
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $73.9M, March 2025
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: arborbio

Arbor Biotechnologies, based in Cambridge, Massachusetts, is a biotechnology firm that specializes in the development of genetic medicines. Founded in 2016, the company is dedicated to revolutionizing the treatment of genetic diseases through advanced gene editing technologies. Arbor focuses on creating programmable DNA editors, which are designed to offer customized solutions for various genetic disorders. Their innovative approach allows for a more precise targeting of genetic issues, which is crucial in the field of personalized medicine. Arbor has attracted significant investment, including a recent $73.9 million in Series C funding, underscoring the confidence investors have in their mission and capabilities. The company actively collaborates with healthcare providers and research organizations, positioning itself as a key player in the biotechnology sector, particularly in the areas of liver and central nervous system diseases. Arbor's commitment to developing functional cures rather than just treatments reflects a forward-thinking strategy in genetic medicine.

4. Horizon Discovery

• Website: horizondiscovery.com
• Ownership type: Corporate
• Headquarters: Cambridge, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 62%, United States (USA) 34%, Other 3%
• Latest funding: $383.0M, November 2020
• Founded year: 2005
• Headcount: 201-500
• LinkedIn: horizon-discovery

Horizon Discovery Ltd. is a biotechnology firm based in Cambridge, England, founded in 2005. The company focuses on gene editing and modulation, offering a comprehensive range of products and services that support researchers in the life sciences sector. Their portfolio includes advanced CRISPR technology, functional genomic screening, and engineered cell models, which are crucial for genetic research and development. Horizon Discovery caters to a wide array of clients in the biotechnology and pharmaceutical industries, providing innovative solutions that enhance research capabilities. The company has also secured significant funding, with a reported amount of $383 million in November 2020, indicating strong investor confidence in their business model and growth prospects.

5. Zymergen, Inc.

• Website: zymergen.com
• Ownership type: Corporate
• Headquarters: Emeryville, California, United States (USA)
• Latest funding: $300.0M, July 2022
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: zymergen-inc-

Zymergen, Inc., founded in 2013 and based in Emeryville, California, is a biotechnology firm that specializes in the intersection of genomics and machine learning. The company develops chemical-producing genetically modified organisms, aiming to provide innovative solutions for chemical production across multiple industries. Zymergen's work primarily targets sectors such as defense and large-scale manufacturing, where their engineered organisms can enhance production processes and efficiency. The company has attracted substantial investment, with a reported funding amount of $300 million as of July 2022, reflecting strong market interest and the potential for growth in their technological applications.

6. Aldevron

• Website: aldevron.com
• Ownership type: Corporate
• Headquarters: Fargo, North Dakota, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $9.6B, June 2021
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: aldevron

Aldevron, founded in 1998 and based in Fargo, North Dakota, is a biotechnology company that specializes in the manufacturing of high-quality plasmid DNA, RNA, proteins, and enzymes. These products are vital for research and clinical applications, particularly in the areas of drug development and gene therapy. Aldevron serves a wide range of clients in the biotechnology and pharmaceutical sectors, providing essential biological materials that support innovative therapies. The company operates with a strong emphasis on quality and regulatory compliance, ensuring that its products meet the rigorous standards required in the life sciences industry. Aldevron has also been involved in significant funding activities, with a reported funding amount of $9.6 billion as of June 2021, which underscores its growth and potential in the market. With a workforce of around 830 employees, Aldevron continues to expand its capabilities and facilities to meet the evolving needs of its clients, including advancements in mRNA manufacturing and CRISPR technologies.

7. Scribe Therapeutics

• Website: scribetx.com
• Ownership type: Venture Capital
• Headquarters: Alameda, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Convertible note, May 2023
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: scribe-therapeutics

Scribe Therapeutics, founded in 2017 and based in Alameda, California, is a biotechnology firm specializing in CRISPR-based genetic medicine. The company is dedicated to developing cutting-edge genetic editing technologies that target genetic diseases. Scribe's innovative platform integrates various CRISPR technologies, allowing for the rapid generation of synthetic CRISPR molecules. Their focus on enhancing delivery methods, activity, and safety in genetic editing positions them as a key player in the biotechnology sector. Scribe collaborates with healthcare providers and pharmaceutical companies, aiming to provide effective solutions for a range of genetic disorders, including neurological and ophthalmological diseases. The company has received recognition for its contributions to the field, including multiple awards highlighting its innovative approaches and potential for future breakthroughs.

8. Inscripta, Inc.

• Website: inscripta.com
• Ownership type: Venture Capital
• Headquarters: Pleasanton, California, United States (USA)
• Employee distribution: United States (USA) 97%, United Kingdom (UK) 3%
• Latest funding: $4.4M, January 2023
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: inscriptainc

Inscripta, Inc. is a biotechnology company based in Pleasanton, California, founded in 2015. The firm specializes in digital genome engineering and synthetic biology, providing innovative solutions aimed at enhancing genome editing and biomanufacturing processes. Their flagship products include the GenoScaler™ Platform, which accelerates the development of optimized strains, and the MAD7® Nuclease, a CRISPR-based tool designed to democratize access to genome editing technologies. Inscripta serves a range of clients, including biotechnology firms and research institutions, helping them improve product development efficiency. The company has also made strategic acquisitions, such as Infinome Biosciences and Sestina Bio, to bolster its capabilities in sustainable biomanufacturing. With a workforce of around 74 employees and a significant portion of its operations based in the United States, Inscripta continues to be an active participant in the biotechnology sector, recently securing funding in January 2023 to support its growth initiatives.

9. Mammoth Biosciences

• Website: mammoth.bio
• Ownership type: Private Equity
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $150.0M, September 2021
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: mammothbio

Mammoth Biosciences is a biotechnology firm based in Brisbane, California, specializing in CRISPR-based therapeutics and diagnostics. Founded in 2017, the company aims to transform patient care through innovative gene editing technologies. Their focus includes developing in vivo gene editing therapeutics and a CRISPR-based detection platform, which has broad applications in healthcare. The company has garnered attention for its ultracompact CRISPR systems, designed to enhance specificity and efficacy in gene editing. With a robust intellectual property portfolio and partnerships with industry leaders, Mammoth is actively working to meet critical medical needs. The company raised $150 million in a Series D funding round in September 2021, indicating strong investor confidence in its mission and capabilities.

10. Evozyne

• Website: evozyne.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $81.0M, September 2023
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: evozyne

Evozyne, founded in 2020 and based in Chicago, Illinois, is a biotechnology firm dedicated to addressing significant health challenges through the development of novel protein systems. The company specializes in creating high-performance therapeutic proteins and gene editing technologies, collaborating with pharmaceutical companies to facilitate drug development. Evozyne employs generative AI and evolutionary principles to design adaptive proteins, aiming to produce life-changing treatments for patients and potentially cure previously untreatable diseases. Recently, Evozyne secured $81 million in Series B funding, which underscores investor confidence in their innovative approach and technology. Their partnerships with industry leaders, including a collaboration with NVIDIA to enhance protein design capabilities, further solidify their position in the biotechnology sector.

11. EdiGene Inc.

• Website: edigene.com
• Ownership type: Private Equity
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Latest funding: Series B, $61.6M, April 2021
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: edigene

EdiGene Inc., founded in 2015 and based in Beijing, China, is a biotechnology firm dedicated to the development of innovative gene editing and therapy solutions. The company aims to address critical unmet medical needs, particularly in cancer and genetic disorders, through its advanced platforms. EdiGene's LEAPER technology focuses on RNA editing, allowing for precise modifications without introducing foreign proteins, while the MAGIC platform enhances immune compatibility in cell therapies. The company has made strides in clinical research, with several projects in various stages of development, including therapies for Duchenne Muscular Dystrophy and other genetic conditions. EdiGene has also secured significant funding, with its last round raising over $61 million in April 2021, indicating strong investor interest and support for its mission. Their active engagement in scientific discourse, including presentations at major conferences, underscores their commitment to advancing the field of genetic engineering.

12. Life Edit Therapeutics

• Website: lifeeditinc.com
• Ownership type: Private
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: lifeedit

Life Edit Therapeutics, founded in 2017 and based in Durham, North Carolina, is a biotechnology firm dedicated to advancing gene editing technologies. The company specializes in developing solutions for genetic disorders, offering a range of products that include RNA-guided nucleases and therapeutic delivery systems. Life Edit's innovative gene editing platform allows for precise targeting of genomic sequences, enabling the development of therapies for complex genetic conditions. Their primary clientele consists of biotech and pharmaceutical companies seeking to enhance their therapeutic development pipelines. Life Edit is also part of the ElevateBio ecosystem, which integrates various enabling technologies and manufacturing capabilities aimed at accelerating the delivery of transformative genetic medicines. The company actively seeks partnerships to further its mission of creating life-changing therapies, demonstrating its commitment to collaboration within the industry.

13. Centaura

• Website: centaura.com
• Ownership type: Private
• Headquarters: Zurich, Zurich, Switzerland
• Employee distribution: United States (USA) 50%, Switzerland 50%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: centaura-ag

Centaura is a private biotechnology company based in Zurich, Switzerland, founded in 2018. With a small team of 11-50 employees, the company is dedicated to advancing gene editing and therapy solutions. Centaura's primary focus is on developing the Human Artificial Chromosome (HAC), a multi-gene delivery platform designed to enhance the capabilities of genetic engineering in human cells. This platform can accept, deliver, and express a variety of genes, including therapeutic proteins and CRISPR/Cas components, without triggering an immune response. Their innovative approach aims to simplify the treatment of complex diseases and improve therapeutic outcomes, making significant strides in the field of gene therapy. The company operates with a balanced employee distribution between the United States and Switzerland, indicating a strategic presence in key markets. Centaura's commitment to addressing intricate medical challenges positions it as a noteworthy entity in the biotechnology industry.

14. SalioGen Therapeutics

• Website: saliogen.com
• Ownership type: Venture Capital
• Headquarters: Lexington, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $115.0M, January 2022
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: saliogen

SalioGen Therapeutics, founded in 2020 and based in Lexington, Massachusetts, is a biotechnology firm dedicated to advancing genetic medicine. The company specializes in developing innovative therapies using its proprietary Gene Coding technology, which enables the integration of large DNA sequences into the genome at specific locations. This method avoids the complications associated with viral vectors and double-stranded breaks, making it a safer and more efficient approach to genetic engineering. SalioGen's primary focus is on treating genetic disorders, with lead programs targeting cystic fibrosis and Stargardt disease. The company has attracted significant venture capital, raising $115 million in its Series B funding round in January 2022, which underscores its potential in the biotechnology space. SalioGen is also exploring applications of its technology in engineered CAR-T cells for cancer and autoimmune diseases, further expanding its impact in the genetic medicine field.

15. Infinome Biosciences

• Website: infinomebio.com
• Ownership type: Corporate
• Headquarters: Boulder, Colorado, United States (USA)
• Latest funding: January 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: infinome-biosciences

Infinome Biosciences is a biotechnology company based in Boulder, Colorado, founded in 2020. It specializes in genome engineering and synthetic biology, providing innovative solutions aimed at improving the efficiency of strain engineering and biomanufacturing processes. The company is known for its development of the GenoScaler™ Platform and MAD7® Nuclease, which are designed to facilitate advanced genetic modification and product development. Infinome's primary clientele includes businesses in the biotechnology and pharmaceutical sectors, which seek cutting-edge tools for genetic engineering. In January 2023, Infinome was acquired by Inscripta, further enhancing its capabilities and reach within the synthetic biology market.

16. HuidaGene Therapeutics

• Website: huidagene.com
• Ownership type: Venture Capital
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 88%, United States (USA) 12%
• Latest funding: Series C, May 2022
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: %e8%be%89%e5%a4%a7%ef%bc%88%e4%b8%8a%e6%b5%b7%ef%bc%89%e7%94%9f%e7%89%a9%e7%a7%91%e6%8a%80%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8

HuidaGene Therapeutics, founded in 2018 and based in Shanghai, China, is a biotechnology firm dedicated to the development of gene editing tools and gene therapies. The company focuses on creating innovative treatments for genetic disorders, with a particular emphasis on neurology and ophthalmology. HuidaGene aims to transform genomic medicine through advanced research and development, serving both patients and healthcare providers. Their pipeline includes therapies for conditions such as MECP2 Duplication Syndrome, Huntington's Disease, and various inherited retinal diseases. The company has made notable progress in its research, including the discovery of CRISPR-Cas13 and Cas12 technologies, and has initiated multiple clinical trials to evaluate the safety and efficacy of its therapies. HuidaGene's commitment to addressing critical health challenges through genomic medicine underscores its relevance in the biotechnology sector.

17. Emendo Biotherapeutics

• Website: emendobio.com
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 96%, United States (USA) 4%
• Latest funding: $250.0M, December 2020
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: emendo-biotheraputics

Emendo Biotherapeutics is a biotechnology company based in New York, specializing in advanced gene editing solutions through CRISPR technology. Founded in 2015 by a group of graduates from the Weizmann Institute, the company aims to improve the precision of gene editing by customizing nucleases and guide-RNAs to target specific genes effectively. Emendo's innovative approach is centered on understanding genetic diseases first, allowing them to devise optimal editing strategies tailored to each condition. Their technology platform is designed to minimize off-target effects, which is crucial for the safe application of gene editing in therapeutic contexts. With a workforce of around 47 employees, primarily based in Israel, Emendo has attracted significant investment, securing $250 million in funding as of December 2020. This financial backing supports their mission to develop novel CRISPR solutions that can potentially transform the treatment of genetic diseases.

18. Cyagen

• Website: cyagen.com
• Ownership type: Venture Capital
• Headquarters: Santa Clara, California, United States (USA)
• Employee distribution: China 77%, United States (USA) 18%, Germany 6%
• Latest funding: Series B, $41.0M, February 2020
• Founded year: 2005
• Headcount: 501-1000
• LinkedIn: cyagen-biosciences

Cyagen Biosciences, founded in 2005 and based in Santa Clara, California, is a biotechnology firm that specializes in custom-engineered animal models and stem cell products. The company serves researchers and institutions in the biosciences sector, providing critical services for genetic modification and model generation. Cyagen is recognized for its expertise in creating genetically modified mice and rats, utilizing advanced techniques such as TurboKnockout and CRISPR. They have established a strong presence in the market, working with over 7,000 bioscience institutions globally and offering a catalog of more than 50,000 mouse and rat models. In 2020, Cyagen secured $41 million in Series B funding, which underscores their growth potential and commitment to advancing medical research. Their facilities are AAALAC accredited, ensuring high standards in animal care and research practices.

19. Recombinetics

• Website: recombinetics.com
• Ownership type: Venture Capital
• Headquarters: Eagan, Minnesota, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $34.0M, August 2018
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: recombinetics-inc.

Recombinetics, founded in 2008 and based in Eagan, Minnesota, is a biotechnology firm focused on gene editing solutions for both biomedical research and agricultural applications. The company offers a range of services, including preclinical research and the development of gene-edited animal models. Their clientele includes researchers and agricultural producers who seek innovative technologies to enhance health outcomes and improve food production sustainability. Recombinetics has made significant strides in the field of animal gene editing, particularly in livestock, and has developed a proprietary gene editing platform that supports their various BioVentures. The company is also involved in regenerative medicine, aiming to improve patient outcomes through advanced therapeutic models. With a recent funding round of $34 million in 2018, Recombinetics is positioned for continued growth and innovation in the genetic engineering space.

20. Tune Therapeutics

• Website: tunetx.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $175.0M, January 2025
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: tunetx

Tune Therapeutics, founded in 2020 and based in Durham, North Carolina, is a biotechnology firm specializing in genetic medicine and epigenomics. The company is at the forefront of developing innovative therapies through its proprietary TEMPO platform, which enables precise regulation of gene expression. This technology allows for the activation, silencing, and fine-tuning of specific genes, targeting chronic and age-related diseases. Tune Therapeutics serves healthcare providers and researchers, providing advanced solutions in gene and cell therapies. The company has recently raised $175 million in Series B funding, reflecting strong investor interest and support for its mission to transform human healthspan through genetic tuning. With a dedicated team of approximately 90 employees, Tune Therapeutics is actively contributing to the evolution of genetic medicine.

21. Ascidian Therapeutics

• Website: ascidian-tx.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $40.0M, November 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: ascidian-therapeutics

Ascidian Therapeutics, founded in 2020 and based in Boston, Massachusetts, is a biotechnology company dedicated to developing RNA therapeutics. The company specializes in RNA exon editing technologies, which aim to provide innovative treatments for genetic diseases. Their initial focus is on Stargardt disease, a condition caused by mutations in the ABCA4 gene that leads to progressive vision loss. Ascidian's unique approach involves rewriting RNA to restore normal protein function, offering a potential solution for patients who currently have no approved treatment options. The company has recently raised $40 million in Series A funding, underscoring its commitment to advancing its research and development pipeline. Ascidian's work combines cutting-edge genomics, computational biology, and deep-sequencing technologies to create a new class of medicines targeting the underlying causes of genetic diseases.

22. HC Bioscience, Inc.

• Website: hcbioscience.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $16.0M, November 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: hc-bioscience

HC Bioscience, Inc., founded in 2021 and based in Cambridge, Massachusetts, is a biotechnology firm dedicated to advancing genomic medicine. The company specializes in a tRNA-based protein editing platform designed to correct genetic mutations, thereby restoring protein function. Their technology allows for precise modifications within the cell's translational machinery, enabling the production of functional proteins from faulty genes without altering the underlying DNA or mRNA. This innovative approach is particularly relevant for researchers and healthcare providers addressing genetic disorders. In November 2022, HC Bioscience secured $16 million in Series A funding, which underscores investor confidence in their potential to impact the field of genetic medicine. The company is actively engaged in developing programs targeting conditions such as Duchenne Muscular Dystrophy and Hemophilia A, showcasing their commitment to translating scientific research into practical medical solutions.

23. Entos Pharmaceuticals

• Website: entospharma.com
• Ownership type: Private
• Headquarters: Edmonton, Alberta, Canada
• Employee distribution: United States (USA) 51%, Canada 49%
• Latest funding: Other (Grant), $4.0M, January 2025
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: entospharmaceuticals

Entos Pharmaceuticals, founded in 2016 and based in Edmonton, Alberta, Canada, is a private biotechnology firm specializing in genetic medicines. The company leverages its proprietary Fusogenix PLV™ technology to create innovative therapies aimed at treating genetic diseases. Their focus on research and development of nucleic acid therapies positions them at the forefront of the biotechnology and pharmaceutical sectors. Entos serves healthcare providers and researchers, providing advanced solutions for patient care. The company has a notable presence in both Canada and the United States, with a significant portion of its workforce located in the U.S. In January 2025, Entos secured $4 million in funding through a grant, underscoring its active engagement in the industry and commitment to advancing genetic medicine.

24. Specific Biologics

• Website: specificbiologics.com
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 100%
• Latest funding: Seed, October 2023
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: specific-biologics

Specific Biologics Inc. is a biotechnology firm based in Toronto, Ontario, Canada, founded in 2017. The company is dedicated to developing next-generation gene editing technologies aimed at addressing genetic diseases at the cellular level. Their flagship platform, Dualase, is designed to cut DNA in a unique manner, creating non-compatible ends that influence cellular DNA repair processes. This innovative approach allows for more precise targeting of genetic diseases, potentially opening doors to treatments that were previously unattainable. Specific Biologics collaborates with healthcare providers and researchers to advance their gene editing solutions, and they are actively building a pipeline of therapeutics based on their Dualase technology. The company is also located in the MaRS Centre, a hub for life sciences, which provides access to top-tier talent and resources in the field. In 2021, they received a therapeutic development award from the Cystic Fibrosis Foundation, highlighting their commitment to impactful research.

Genetic Engineering Insights: Key Companies

Want to Find More Genetic Engineering Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!